Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer

Summary

Previous reports suggest benefit of neoadjuvant chemoradiation treatment for borderline resectable pancreas cancer. This study is a multicenter prospective randomized phase II/III study of neoadjuvant chemoradiation with gemcitabine in patients with borderline resectable pancreas cancer. The study is designed in 2 arms, one with upfront surgery and the other with neoadjuvant chemoradiation therapy.

Timeline

Start

2011-11

Primary completion

2018-01

Completion

2018-01

Drugs

Indications